OncoMatch/Clinical Trials/NCT01935778
Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH
Is NCT01935778 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Docetaxel and capecitabine and oxaliplatin and capecitabine and oxaliplatin for gastric cancer, adjuvant chemotherapy, xo.
Treatment: Docetaxel and capecitabine and oxaliplatin · capecitabine and oxaliplatin — multicenter, open label, randomaized, phase III The role of post surgery adjuvant chemotherapy is becoming more and more important in AGC (advance gastric cancer). S-1 and combined therapy of Capecitabine and Oxaliplatin are currently accepted as a standard therapy among the AGC patients who were performed gastrectomy from the D2 surgery. However, many improvements will be needed in stage IIIB and IV. Combined chemotherapy of Docetaxel, Capecitabine, and Oxaliplatin may be considered as one of the best treatments for IIB and IV(M0) stage AGC patients who were performed gastrectomy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Disease stage
Required: Stage IIIB, IV (TNM)
TNM(tumor/lymph node/metastasis) stage of IIIB or IV on post-operative staging. Gastric or gastroesophageal junction adenocarcinoma with distant metastasis (M1) including distant lymph node (behind the pancreas, along the aorta, portal vein, behind the peritoneum, mesenteric lymph node) [excluded]
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: surgery — radical resection with wide lymph node dissection
Patients who underwent radical resection with wide lymph node dissection
Cannot have received: surgery for neoplasm in stomach
Patients who underwent surgery for neoplasm in stomach in the past
Cannot have received: alleviator, adjuvant chemotherapy, or neoadjuvant chemotherapy and/or radiotherapy and/or immunotherapy
Patients who received alleviator, adjuvant chemotherapy, or neoadjuvant chemotherapy and/or radiotherapy and/or immunotherapy in the past for treatment of gastric cancer
Lab requirements
Blood counts
absolute neutrophil count < 1.5 x 10^9/l, platelet < 100 x 10^9/l, hemoglobin ≤ 9 g/dl [excluded]
Kidney function
serum creatinine > 1.5 x uln or creatinine clearance ≤ 50 ml/min [excluded]
Liver function
ast > 2.5 x uln, alt > 2.5 x uln, alp > 2.5 x uln, total bilirubin > 1.5 x uln [excluded]
Cardiac function
any of the following within 6 months prior to the study recruitment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass, nyha class iii or iv congestive heart failure, stroke or transient ischemic attack, serious cardiac arrhythmia requiring treatment [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify